Stiripentol Production Cost Reports

The report provides a detailed analysis essential for establishing a Stiripentol production plant. It encompasses all critical aspects necessary for Stiripentol production, including the cost of Stiripentol production, Stiripentol plant cost, Stiripentol production costs, and the overall Stiripentol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Stiripentol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Stiripentol is an anticonvulsant medication that is approved as adjunctive therapy for seizures associated with Dravet syndrome. It is used in combination with clobazam for patients aged 6 months or older weighing at least 7 kg.

It reduces generalised tonic-clonic seizure frequency by 50-75% in many cases and improves quality of life, cognitive outcomes, and reduces hospitalisations. It has approvals from the FDA and EMA as an orphan drug for this rare condition. It improves GABA calming signals, boosts clobazam by blocking CYP enzymes, stops T-type calcium channels, and protects neurons by inhibiting lactate dehydrogenase. Its common side effects include drowsiness, loss of appetite, weight loss, nausea, agitation, ataxia (poor coordination), tremor, insomnia, hypotonia (low muscle tone), and vomiting.

The Stiripentol market is driven by the growing cases of rare epileptic disorders. Its usage in the treatment of Dravet syndrome, along with regulatory incentives for orphan drugs, contributes to its market growth. The FDA and EMA approvals as adjunctive therapy and its long-term seizure reduction efficacy in pediatric patients expand its applications. The industrial Stiripentol procurement is driven by orphan status, limiting generic competition to maintain high pricing.

Also, the reliance on a sole manufacturer or supply, and economic evaluations favouring cost-effectiveness in reducing hospitalisations despite premium costs, affects its market dynamics. The strict regulations for pediatric formulations and competition from emerging therapies like cannabidiol (Epidiolex), impacts its sourcing.

Raw Material for Stiripentol Production

According to the Stiripentol production plant project report, the key raw materials used in the production of Stiripentol include 3,4 Dihydroxybenzaldehyde, Methylene Dihalide, and 3,3 Dimethyl 2 Butanone.

Production Process of Stiripentol

The extensive Stiripentol production cost report consists of the following major industrial production process:

• From 3,4 Dihydroxybenzaldehyde: The production of Stiripentol involves a one pot process. In this process, 3,4 dihydroxybenzaldehyde is cyclised with a methylene source under basic conditions to form the benzo[d]dioxole aldehyde. This then goes through a Knoevenagel condensation in the same vessel with 3,3 dimethyl 2 butanone in the presence of a carbonate base and a phase transfer catalyst that leads to the formation of α,β unsaturated ketone. This is followed by an in situ Luche reduction using sodium borohydride and cerium(III) chloride to selectively reduce the double bond and gives Stiripentol as the final product.

Stiripentol has the molecular formula of C14H18O3 and a molecular weight of 234.29 g/mol. It appears as a white to pale yellow crystalline solid or powder in the solid state. It has a melting point of 73-74 degree Celsius, has a logP value of 2.94, making it moderately lipophilic. It has a pKa of 14.2 and water solubility of about 0.405 mg/mL. It is sparingly soluble in chloroform but soluble in acetone, ethanol, ether, acetonitrile, and dichloromethane. It has 3 hydrogen bond acceptors, 1 donor, a polar surface area of 38.69 Ų, and 3 rotatable bonds. It has a refractivity of 66.77 m³·mol?¹ and polarizability of 26.21 ų. It also has low aqueous bioavailability because of its insolubility and metabolism.